News

AstraZeneca (LSE:AZN) received EU approval for its cancer treatment Imfinzi, marking a significant product-related milestone.
Every bladder cancer journey is different, and no single treatment or diagnostic path fits everyone. According to patients who have experienced bladder cancer, the best care for you will depend on ...
Nine years after my bladder cancer diagnosis, I reflect on its recurrence, caregiving, grief, and my new life with leukemia ...
The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
Beat bladder cancer with early detection! Expert insights reveal how a multidisciplinary approach can improve treatment outcomes in India. Learn more about effective care.
The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...
Bladder Cancer is a disease where cancer cells form in the tissues of the bladder. More common in males than females over 55 ...
Bladder cancer, often misunderstood, affects both men and women, not just the elderly. While smoking is a significant risk ...
The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, ...
Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...
Joseph Jacob, MD, discusses the promising impact of TAR-200.
Multidisciplinary care, a collaborative approach where various healthcare disciplines come together, is essential for treating those with prostate cancer.